A randomized, crossover, head-to-head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: The Comparing EPA to DHA (ComparED) Study

American Journal of Clinical Nutrition

Volumn 104, Issue 2, 2016, Pages 280-287

  Allaire, Janie ^a   Couture, Patrick ^a,b   Leclerc, Myriam ^a   Charest, Amélie ^a   Marin, Johanne ^a   Lépine, Marie Claude ^a   Talbot, Denis ^b,c   Tchernof, André ^a,b,d   Lamarche, Benoit ^a  

^a Institute of Nutraceuticals and Functional Foods   (Canada)

^b Department of Virology   (United States)

^c UNIVERSITÉ LAVAL   (Canada)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

DHA; EPA; Inflammation; Men and women; Randomized controlled trial; Risk factors

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; INTERLEUKIN 18; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; CHOLESTEROL; CYTOKINE; TUMOR NECROSIS FACTOR;

ABDOMINAL OBESITY; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INFLAMMATION; LIPID BLOOD LEVEL; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MENSTRUAL CYCLE; MIDDLE AGED; PHOSPHOLIPID BLOOD LEVEL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SUPPLEMENTATION; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION; UNSPECIFIED SIDE EFFECT; WAIST CIRCUMFERENCE; AGED; BLOOD; DIETARY SUPPLEMENT; METABOLISM;

ADIPONECTIN; ADULT; AGED; BIOMARKERS; C-REACTIVE PROTEIN; CHOLESTEROL; CROSS-OVER STUDIES; CYTOKINES; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-18; MALE; MIDDLE AGED; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84980338819     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.116.131896     Document Type: Article

References (33)

1. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 2009;6:399-409.
2. Libby P, Ridker PM, Hansson GK, Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009;54:2129-38.
3. Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 2008;197:12-24.
4. Calder PC. Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance. Biochim Biophys Acta 2015;1851:469-84.
5. Li K, Huang T, Zheng J, Wu K, Li D. Effect of marine-derived n-3 polyunsaturated fatty acids on C-reactive protein, interleukin 6 and tumor necrosis factor alpha: a meta-analysis. PLoS One 2014;9: e88103.
6. Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and metaanalysis. Curr Atheroscler Rep 2011;13:474-83.
7. Vannice G, Rasmussen H. Position of the academy of nutrition and dietetics: dietary fatty acids for healthy adults. J Acad Nutr Diet 2014; 114:136-53.
8. Phang M, Sinclair AJ, Lincz LF, Garg ML. Gender-specific inhibition of platelet aggregation following omega-3 fatty acid supplementation. Nutr Metab Cardiovasc Dis 2012;22:109-14.
9. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 2005;366:1059-62.
10. Landgren BM, Collins A, Csemiczky G, Burger HG, Baksheev L, Robertson DM. Menopause transition: annual changes in serum hormonal patterns over the menstrual cycle in women during a nine-year period prior to menopause. J Clin Endocrinol Metab 2004;89:2763-9.
11. Bell HK, Bloomer RJ. Impact of serum estradiol on postprandial lipemia, oxidative stress, and inflammation across a single menstrual cycle. Gend Med 2010;7:166-78.
12. Karim R, Stanczyk FZ, Hodis HN, Cushman M, Lobo RA, Hwang J, Mack WJ. Associations between markers of inflammation and physiological and pharmacological levels of circulating sex hormones in postmenopausal women. Menopause 2010;17:785-90.
13. Airlie LT, Roche A, Martorel R. Standardization of anthropometric measurements. The Airlie (VA) Concensus Conference. Champaign (IL): Human Kinetics; 1988.
14. Pirro M, Bergeron J, Dagenais GR, Bernard PM, Cantin B, Despres JP, Lamarche B. Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. Arch Intern Med 2001;161:2474-80.
15. Kroger E, Verreault R, Carmichael PH, Lindsay J, Julien P, Dewailly E, Ayotte P, Laurin D. Omega-3 fatty acids and risk of dementia: the Canadian Study of Health and Aging. Am J Clin Nutr 2009;90: 184-92.
16. Labonté ME, Cyr A, Baril-Gravel L, Royer MM, Lamarche B. Validity and reproducibility of a web-based, self-administered food frequency questionnaire. Eur J Clin Nutr 2012;66:166-73.
17. Bouchard C, Tremblay A, Leblanc C, Lortie G, Savard R, Theriault G. A method to assess energy expenditure in children and adults. Am J Clin Nutr 1983;37:461-7.
18. Richard C, Couture P, Desroches S, Lamarche B. Effect of the Mediterranean diet with and without weight loss on markers of inflammation in men with metabolic syndrome. Obesity (Silver Spring) 2013;21: 51-7.
19. Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GB, McPherson R, Francis GA, Poirier P, Lau DC, Grover S, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013;29:151-67.
20. Bland JM, Altman DG. Best (but oft forgotten) practices: testing for treatment effects in randomized trials by separate analyses of changes from baseline in each group is a misleading approach. Am J Clin Nutr 2015;102:991-4.
21. Chakraborty H, Gu H. A mixed model approach for intent-to-treat analysis in longitudinal clinical trials with missing values. Report No. MR-0009-0903. Research Triangle Park (NC): RTI Press; 2009.
22. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Int J Surg 2011;9:672-7.
23. Myhrstad MC, Retterstol K, Telle-Hansen VH, Ottestad I, Halvorsen B, Holven KB, Ulven SM. Effect of marine n-3 fatty acids on circulating inflammatory markers in healthy subjects and subjects with cardiovascular risk factors. Inflamm Res 2011;60:309-19.
24. Mori TA, Woodman RJ, Burke V, Puddey IB, Croft KD, Beilin LJ. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med 2003;35:772-81.
25. Azizi-Soleiman F, Jazayeri S, Eghtesadi S, Rajab A, Heidari I, Vafa MR, Gohari MR. Effects of pure eicosapentaenoic and docosahexaenoic acids on oxidative stress, inflammation and body fat mass in patients with type 2 diabetes. Int J Prev Med 2013;4:922-8.
26. Tsunoda F, Lamon-Fava S, Asztalos BF, Iyer LK, Richardson K, Schaefer EJ. Effects of oral eicosapentaenoic acid versus docosahexaenoic acid on human peripheral blood mononuclear cell gene expression. Atherosclerosis 2015;241:400-8.
27. von Frankenberg AD, Silva FM, de Almeida JC, Piccoli V, do Nascimento FV, Sost MM, Leitao CB, Remonti LL, Umpierre D, Reis AF, et al. Effect of dietary lipids on circulating adiponectin: a systematic review with meta-analysis of randomised controlled trials. Br J Nutr 2014;112: 1235-50.
28. C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC), Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T, Engert JC, Clarke R, Davey-Smith G, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ 2011; 342:d548.
29. Ridker PM. The JUPITER trial: results, controversies, and implications for prevention. Circ Cardiovasc Qual Outcomes 2009;2:279-85.
30. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008; 54:24-38.
31. Bannenberg G, Serhan CN. Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochim Biophys Acta 2010; 1801:1260-73.
32. Rudkowska I, Paradis AM, Thifault E, Julien P, Tchernof A, Couture P, Lemieux S, Barbier O, Vohl MC. Transcriptomic and metabolomic signatures of an n-3 polyunsaturated fatty acids supplementation in a normolipidemic/normocholesterolemic Caucasian population. J Nutr Biochem 2013;24:54-61.
33. Mori TA, Burke V, Puddey IB, Watts GF, O'Neal DN, Best JD, Beilin LJ. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 2000;71:1085-94.